A Phase 2 interventional study of Roflumilast and Placebo in Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation, sponsored by AstraZeneca. Terminated at 2 sites in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-02-14.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 18th largest by enrollment, is one of 4 that started in 2012, is one of 4 in phase 2, and was the 16th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 8
First in 2003; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 154 across the 32 interventional studies. Of the 30 that completed or were terminated, 17 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 32 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 121st largest by enrollment of the 194 interventional ones that give a count, is one of 18 that started in 2012, is one of 54 in phase 2, and was the 113th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing roflumilast in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07795086Sidra AzizComparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). In addition, the potential benefit of roflumilast on severity and recovery periods of acute COPD exacerbations will be assessed using patient diaries and questionnaires.
Participants will be asked whether they agree to participate in the measurements of arterial stiffness. Participants who agree will be included in the substudy, with the target of 60 patients with arterial stiffness measurements to complete the trial.
Study was terminated due to difficulty in identifying further eligible patients for this exploratory study within a reasonable time.
Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
added on to standard therapy for acute COPD exacerbations
Drug: Roflumilast
added on to standard therapy for acute COPD exacerbations
Drug: Placebo
500 µg tablet, od, oral administration in the morning after breakfast
tablet, od, oral administration in the morning after breakfast
Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. An Analysis of Covariance (ANCOVA) model was used with neutrophil count at Baseline and treatment as independent variables, fixed effects.
Time frame: Baseline and Day 14
Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. An Analysis of Covariance (ANCOVA) model was used with neutrophil count at Baseline and treatment as independent variables, fixed effects.
Time frame: Baseline and Day 14
Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) and were determined with a Neubauer hemocytometer.
Time frame: Day 14
Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) and were determined with a Neubauer hemocytometer.
Time frame: Day 14
Change From Baseline in Sputum Marker Total Cells (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Total Cells (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Percentage of Neutrophils (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of neutrophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Percentage of Neutrophils (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of neutrophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction. A negative change from Baseline indicates improvement.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Percentage of Macrophages (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of macrophages was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Percentage of Macrophages (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of macrophages was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Percentage of Eosinophils (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of eosinophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Percentage of Eosinophils (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of eosinophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Percentage of Lymphocyte (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of lymphocytes was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Percentage of Lymphocytes (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of lymphocytes was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-6 (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-6 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-6 (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-6 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-8 (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-8 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Concentration of Interleukin (IL)-8 (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-8 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Concentration of Myeloperoxidase (MPO) (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker MPO was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Concentration of Myeloperoxidase (MPO) (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker MPO was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Concentration of Neutrophil Elastase (Initial Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker Neutrophil Elastase was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Sputum Marker Concentration of Neutrophil Elastase (Extended Approach)
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker Neutrophil Elastase was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker Interleukin (IL)-6 (Initial Approach)
Blood was collected and serum biomarker IL-6 was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker Interleukin (IL)-6 (Extended Approach)
Blood was collected and serum biomarker IL-6 was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker Interleukin-1 Beta (IL-1β) (Initial Approach)
Blood was collected and serum biomarker IL-1β was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker IL-1β (Extended Approach)
Blood was collected and serum biomarker IL-1β was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker C-reactive Protein (CRP) (Initial Approach)
Blood was collected and serum biomarker CRP was measured using Roche Modular Analytics E 170 Module. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker C-reactive Protein (CRP) (Extended Approach)
Blood was collected and serum biomarker CRP was measured using Roche Modular Analytics E 170 Module. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker Fibrinogen (Initial Approach)
Biomarker Plasma fibrinogen was determined using the method described by Clauss. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker Fibrinogen (Extended Approach)
Biomarker Plasma fibrinogen was determined using the method described by Clauss. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker Glucose (Initial Approach)
Blood was collected and analyzed for serum glucose levels. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Blood Biomarker Glucose (Extended Approach)
Blood was collected and analyzed for serum glucose levels. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Forced Expiratory Volume (FEV1) (Initial Approach)
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Forced Expiratory Volume (FEV1) (Extended Approach)
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Forced Vital Capacity (FVC) (Initial Approach)
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in Forced Vital Capacity (FVC) (Extended Approach)
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in FEV1/FVC (Initial Approach)
FEV1/FVC is the percentage of the vital capacity which is expired in the first second of maximal expiration. In healthy patients the FEV1/FVC is usually around 70%. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Change From Baseline in FEV1/FVC (Extended Approach)
FEV1/FVC is the percentage of the vital capacity which is expired in the first second of maximal expiration. In healthy patients the FEV1/FVC is usually around 70%. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
Time frame: Baseline and Day 7, Day 14, Day 28 and Day 56
Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Initial Approach)
The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Extended Approach)
The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Initial Approach)
The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst). A negative change from Baseline indicates improvement. Covariates for MMRM are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Chronic Obstructive Pulmonary Assessment Test (CAT) Weekly Averages (Extended Approach)
The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst). A negative change from Baseline indicates improvement. Covariates for MMRM are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Initial Approach)
The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status.
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Extended Approach)
The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status.
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Initial Approach)
The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, time point, treatment by time point and baseline by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Exacerbations of Chronic Pulmonary Disease Test (EXACT-PRO) Weekly Averages (Extended Approach)
The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, time point, treatment by time point and baseline by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Diaries Peak Expiratory Flow (PEF) Weekly Average (Initial Approach)
Morning post-medication PEF (the best of 3 attempts measured with a mini-Wright peak-flow meter) was recorded in a daily diary. A positive change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Diaries Peak Expiratory Flow (PEF) Weekly Average (Extended Approach)
Morning post-medication PEF (the best of 3 attempts measured with a mini-Wright peak-flow meter) was recorded in a daily diary. A positive change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Diaries Symptom Score Weekly Average (Initial Approach)
Any increase in the following respiratory symptoms: dyspnea, sputum purulence, sputum amount, wheeze, sore throat, cough, fever, symptoms of a common cold, ie, nasal congestion and discharge over the previous 24 hours were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Diaries Symptom Score Weekly Average (Extended Approach)
Any increase in the following respiratory symptoms: dyspnea, sputum purulence, sputum amount, wheeze, sore throat, cough, fever, symptoms of a common cold, ie, nasal congestion and discharge over the previous 24 hours were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Diaries Treatment Score Weekly Average (Initial Approach)
Any changes in the participant's usual treatment were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Diaries Treatment Score Weekly Average (Extended Approach)
Any changes in the participant's usual treatment were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Diaries Hours Out of the Home Weekly Average (Initial Approach)
Estimates of the length of time the participants were out of their own home on the previous day were recorded in a daily diary. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Change From Stable State in Diaries Hours Out of the Home Weekly Average (Extended Approach)
Estimates of the length of time the participants were out of their own home on the previous day were recorded in a daily diary. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
Time frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7 and 8
Exacerbation Length (Initial Approach)
Exacerbation length is the period from start of increased symptoms to end of increased symptoms; the last day of an exacerbation was to be followed by 2 days without symptom entries in the diary.
Time frame: 8 Weeks
Exacerbation Length (Extended Approach)
Exacerbation length is the period from start of increased symptoms to end of increased symptoms; the last day of an exacerbation was to be followed by 2 days without symptom entries in the diary.
Time frame: 8 Weeks
Change From Baseline in Aortic Pulse Wave Velocity in a Subset of Participants (Initial Approach)
Carotid-femoral aortic pulse wave velocity (aPWV) will be measured in a subset of participants to determine changes in arterial stiffness. A negative change from Baseline indicates improvement. Covariates for MMRM are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Days 14 and 28
Change From Baseline in Aortic Pulse Wave Velocity in a Subset of Participants (Extended Approach)
Carotid-femoral aortic pulse wave velocity (aPWV) will be measured in a subset of participants to determine changes in arterial stiffness. A negative change from Baseline indicates improvement. Covariates for MMRM are baseline value, treatment, visit, and treatment by visit interaction.
Time frame: Baseline and Days 14 and 28
Participants took part in the study at 1 investigative site in the United Kingdom from 16 February 2012 to 25 March 2014.
| Milestone | Roflumilast 500 μg | Placebo | Roflumilast 500 µg (Cycle 2) | Placebo (Cycle 2) |
|---|---|---|---|---|
| Started | 38 | 43 | 0 | 0 |
| Completed | 27 | 40 | 0 | 0 |
| Not completed | 11 | 3 | 0 | 0 |
| Withdrew: Adverse event | 10 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
| Milestone | Roflumilast 500 μg | Placebo | Roflumilast 500 µg (Cycle 2) | Placebo (Cycle 2) |
|---|---|---|---|---|
| Started | 0 | 0 | 10 | 4 |
| Completed | 0 | 0 | 5 | 4 |
| Not completed | 0 | 0 | 5 | 0 |
| Withdrew: Adverse event | 0 | 0 | 5 | 0 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. An Analysis of Covariance (ANCOVA) model was used with neutrophil count at Baseline and treatment as independent variables, fixed effects.
| 10^6 cells/gram sputum | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Initial Approach) | -18.705 ± 2.263 | -20.109 ± 1.995 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. An Analysis of Covariance (ANCOVA) model was used with neutrophil count at Baseline and treatment as independent variables, fixed effects.
| 10^6 cells/gram sputum | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change From Baseline in Sputum Neutrophil Counts at Day 14 Post Exacerbation (Extended Approach) | -19.569 ± 1.906 | -19.157 ± 1.855 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) and were determined with a Neubauer hemocytometer.
| percentage of participants | Roflumilast 500 μg | Placebo |
|---|---|---|
| Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Initial Approach) | 37.5 (15.2 to 64.6) | 55.2 (35.7 to 73.6) |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) and were determined with a Neubauer hemocytometer.
| percentage of participants | Roflumilast 500 μg | Placebo |
|---|---|---|
| Percentage of Participants Whose Sputum Neutrophil Counts Returned to Stable State at Day 14 (Extended Approach) | 45.0 (23.1 to 68.5) | 51.6 (33.1 to 69.8) |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| 10^6 cells/gram sputum | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=35, 39) | -25.559 ± 3.529 | -27.563 ± 3.334 |
| Change at Day 14 (n=32, 38) | -21.813 ± 2.706 | -25.111 ± 2.505 |
| Change at Day 28 (n=25, 37) | -29.200 ± 4.022 | -22.218 ± 3.362 |
| Change at Day 56 (n=24, 33) | -24.477 ± 2.708 | -26.474 ± 2.341 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Total cell count (absolute number of nonsquamous cells per gram of the original sputum sample) were determined using a Neubauer hemocytometer. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| 10^6 cells/gram sputum | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=45, 43) | -26.634 ± 3.030 | -26.335 ± 3.124 |
| Change at Day 14 (n=41, 42) | -23.512 ± 2.448 | -25.332 ± 2.471 |
| Change at Day 28 (n=30, 40) | -29.023 ± 3.347 | -22.920 ± 2.947 |
| Change at Day 56 (n=28, 36) | -19.551 ± 3.920 | -26.855 ± 3.536 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of neutrophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| percentage of neutrophils | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=30, 35) | -11.325 ± 3.837 | -14.484 ± 3.559 |
| Change at Day 14 (n=31, 37) | -16.770 ± 3.983 | -20.346 ± 3.550 |
| Change at Day 28 (n=24, 34) | -27.760 ± 5.275 | -13.837 ± 4.498 |
| Change at Day 56 (n=16, 30) | -19.663 ± 5.561 | -17.047 ± 4.229 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of neutrophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction. A negative change from Baseline indicates improvement.
| percentage of neutrophils | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 39) | -14.637 ± 3.748 | -16.060 ± 3.713 |
| Change at Day 14 (n=39, 40) | -20.690 ± 3.758 | -21.052 ± 3.678 |
| Change at Day 28 (n=29, 36) | -29.848 ± 4.721 | -14.664 ± 4.371 |
| Change at Day 56 (n=20, 32) | -21.327 ± 5.009 | -17.328 ± 4.188 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of macrophages was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| percentage of macrophages | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=30, 35) | 11.393 ± 3.837 | 15.430 ± 3.559 |
| Change at Day 14 (n=31, 37) | 16.062 ± 3.929 | 20.774 ± 3.506 |
| Change at Day 28 (n=24, 34) | 27.535 ± 5.284 | 13.382 ± 4.503 |
| Change at Day 56 (n=16, 30) | 16.593 ± 5.539 | 15.877 ± 4.171 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of macrophages was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| percentage of macrophages | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 39) | 14.679 ± 3.740 | 17.228 ± 3.704 |
| Change at Day 14 (n=39, 40) | 20.331 ± 3.745 | 21.599 ± 3.667 |
| Change at Day 28 (n=29, 36) | 29.510 ± 4.717 | 14.463 ± 4.367 |
| Change at Day 56 (n=20, 32) | 19.075 ± 5.003 | 16.322 ± 4.156 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of eosinophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| percentage of eosinophils | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=30, 35) | -0.259 ± 0.245 | -0.100 ± 0.225 |
| Change at Day 14 (n=31, 37) | -0.110 ± 0.326 | -0.188 ± 0.288 |
| Change at Day 28 (n=24, 34) | 0.043 ± 1.209 | 1.597 ± 1.020 |
| Change at Day 56 (n=16, 30) | 2.187 ± 2.278 | 1.086 ± 1.766 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of eosinophils was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| percentage of macrophages | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 39) | -0.341 ± 0.206 | -0.141 ± 0.202 |
| Change at Day 14 (n=39, 40) | -0.174 ± 0.271 | -0.214 ± 0.263 |
| Change at Day 28 (n=29, 36) | 0.031 ± 1.044 | 1.518 ± 0.952 |
| Change at Day 56 (n=20, 32) | 1.714 ± 1.969 | 0.913 ± 1.655 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of lymphocytes was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| percentage of lymphocytes | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=30, 35) | 0.229 ± 0.353 | 0.182 ± 0.326 |
| Change at Day 14 (n=31, 37) | 0.430 ± 0.254 | 0.295 ± 0.225 |
| Change at Day 28 (n=24, 34) | 0.039 ± 0.183 | -0.325 ± 0.155 |
| Change at Day 56 (n=16, 30) | -0.095 ± 0.187 | -0.051 ± 0.137 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Aliquots of a cell suspension prepared from the sputum sample were used to prepare cytospin slides that were stained with Diff-Quik for differential cell counts. 100 cells were counted and the percentage of lymphocytes was determined. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| percentage of lymphocytes | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 39) | 0.109 ± 0.308 | -0.015 ± 0.303 |
| Change at Day 14 (n=39, 40) | 0.309 ± 0.250 | 0.195 ± 0.243 |
| Change at Day 28 (n=29, 36) | -0.118 ± 0.173 | -0.431 ± 0.158 |
| Change at Day 56 (n=20, 32) | -0.203 ± 0.164 | -0.208 ± 0.132 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-6 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| pg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=31, 38) | -1317.400 ± 143.748 | -934.624 ± 133.217 |
| Change at Day 14 (n=30, 35) | -822.715 ± 221.328 | -695.955 ± 206.201 |
| Change at Day 28 (n=22, 35) | -1232.929 ± 212.663 | -955.365 ± 174.734 |
| Change at Day 56 (n=22, 29) | -1042.097 ± 225.619 | -996.485 ± 196.729 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-6 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| pg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 42) | -1207.678 ± 133.298 | -923.325 ± 130.533 |
| Change at Day 14 (n=36, 39) | -725.454 ± 195.921 | -705.849 ± 192.890 |
| Change at Day 28 (n=26, 38) | -1115.741 ± 200.367 | -877.871 ± 172.950 |
| Change at Day 56 (n=26, 32) | -860.191 ± 206.289 | -962.342 ± 189.817 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-8 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| pg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=31, 38) | -174718.396 ± 45481.710 | -227274.816 ± 41821.023 |
| Change at Day 14 (n=30, 35) | -149198.139 ± 47388.834 | -199515.687 ± 43965.789 |
| Change at Day 28 (n=22, 35) | -255317.294 ± 70915.154 | -160587.365 ± 57944.793 |
| Change at Day 56 (n=21, 29) | -204731.356 ± 50404.332 | -223918.341 ± 43039.568 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker IL-8 was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| pg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 42) | -193222.856 ± 39595.196 | -215296.477 ± 38432.424 |
| Change at Day 14 (n=36, 39) | -172069.810 ± 41341.330 | -195751.307 ± 40449.866 |
| Change at Day 28 (n=26, 38) | -264788.038 ± 62440.420 | -160441.028 ± 53963.528 |
| Change at Day 56 (n=25, 32) | -168204.970 ± 51760.361 | -205822.814 ± 46476.985 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker MPO was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| ng/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=31, 38) | -9253.786 ± 1997.077 | -4521.397 ± 1863.867 |
| Change at Day 14 (n=30, 35) | -8072.784 ± 2144.895 | -6318.878 ± 2002.939 |
| Change at Day 28 (n=22, 35) | -13744.824 ± 2476.123 | -5944.184 ± 2041.587 |
| Change at Day 56 (n=22, 29) | -10248.612 ± 2578.146 | -9478.460 ± 2234.238 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker MPO was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| ng/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 42) | -8606.357 ± 1747.094 | -4380.803 ± 1713.047 |
| Change at Day 14 (n=36, 39) | -8380.855 ± 1871.930 | -5929.775 ± 1843.806 |
| Change at Day 28 (n=26, 38) | -12692.279 ± 2220.374 | -5351.001 ± 1933.964 |
| Change at Day 56 (n=26, 32) | -9424.227 ± 2275.981 | -8527.766 ± 2078.411 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker Neutrophil Elastase was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| µg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=31, 38) | -222995.020 ± 14887.254 | -224606.396 ± 13669.986 |
| Change at Day 14 (n=30, 35) | -149211.318 ± 39523.470 | -125385.276 ± 36629.962 |
| Change at Day 28 (n=22, 35) | -200905.068 ± 25432.984 | -149865.936 ± 20549.567 |
| Change at Day 56 (n=21, 30) | -141985.838 ± 28278.566 | -169389.587 ± 23767.879 |
Sputum samples were collected and processed at the investigational site according to their standard procedures. Sputum inflammatory marker Neutrophil Elastase was quantified by commercial sandwich enzyme-linked immunosorbent assays (ELISA). A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| µg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 42) | -202235.344 ± 12993.506 | -206912.465 ± 12543.143 |
| Change at Day 14 (n=36, 39) | -143831.510 ± 34043.871 | -110144.325 ± 33211.578 |
| Change at Day 28 (n=26, 38) | -183452.324 ± 22560.241 | -130613.019 ± 19255.852 |
| Change at Day 56 (n=25, 33) | -118129.436 ± 25397.042 | -156544.533 ± 22550.054 |
Blood was collected and serum biomarker IL-6 was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| pg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 41) | -12.469 ± 0.782 | -11.904 ± 0.742 |
| Change at Day 14 (n=33, 41) | -1.973 ± 1.918 | -5.728 ± 1.730 |
| Change at Day 28 (n=28, 40) | -8.108 ± 2.360 | -7.243 ± 1.997 |
| Change at Day 56 (n=27, 40) | -11.665 ± 1.129 | -9.431 ± 0.937 |
Blood was collected and serum biomarker IL-6 was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| pg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=47, 45) | -12.314 ± 0.652 | -11.802 ± 0.665 |
| Change at Day 14 (n=43, 45) | 1.607 ± 2.543 | -6.069 ± 2.490 |
| Change at Day 28 (n=33, 44) | -7.587 ± 2.088 | -7.619 ± 1.838 |
| Change at Day 56 (n=32, 44) | -10.811 ± 1.064 | -9.604 ± 0.918 |
Blood was collected and serum biomarker IL-1β was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| pg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 41) | 1.274 ± 0.682 | 0.378 ± 0.647 |
| Change at Day 14 (n=33, 41) | 0.217 ± 0.359 | 0.495 ± 0.324 |
| Change at Day 28 (n=28, 40) | 0.657 ± 0.431 | 0.541 ± 0.366 |
| Change at Day 56 (n=27, 40) | -0.003 ± 0.329 | 0.464 ± 0.288 |
Blood was collected and serum biomarker IL-1β was quantified using commercial sandwich ELISA. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| pg/mL | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=47, 45) | 0.350 ± 0.590 | -1.002 ± 0.602 |
| Change at Day 14 (n=43, 45) | -0.394 ± 0.355 | -0.841 ± 0.349 |
| Change at Day 28 (n=33, 44) | -0.139 ± 0.414 | -0.757 ± 0.368 |
| Change at Day 56 (n=32, 44) | -0.799 ± 0.333 | -0.806 ± 0.312 |
Blood was collected and serum biomarker CRP was measured using Roche Modular Analytics E 170 Module. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| mg/liter(L) | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 41) | -15.579 ± 0.485 | -16.518 ± 0.461 |
| Change at Day 14 (n=33, 41) | 4.836 ± 4.249 | -4.369 ± 3.812 |
| Change at Day 28 (n=28, 38) | -9.179 ± 4.110 | -8.018 ± 3.533 |
| Change at Day 56 (n=26, 40) | -14.889 ± 1.395 | -13.057 ± 1.133 |
Blood was collected and serum biomarker CRP was measured using Roche Modular Analytics E 170 Module. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| mg/L | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=47, 45) | -16.166 ± 0.410 | -16.901 ± 0.417 |
| Change at Day 14 (n=43, 45) | 5.720 ± 3.600 | -5.257 ± 3.518 |
| Change at Day 28 (n=33, 42) | -8.250 ± 3.802 | -9.254 ± 3.375 |
| Change at Day 56 (n=31, 44) | -15.152 ± 1.219 | -13.793 ± 1.034 |
Biomarker Plasma fibrinogen was determined using the method described by Clauss. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| umol/L | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=34, 39) | -3.916 ± 0.286 | -3.976 ± 0.261 |
| Change at Day 14 (n=33, 38) | 0.404 ± 0.625 | -0.184 ± 0.571 |
| Change at Day 28 (n=27, 36) | 0.210 ± 0.676 | 0.014 ± 0.567 |
| Change at Day 56 (n=26, 38) | -2.127 ± 0.625 | -1.144 ± 0.515 |
Biomarker Plasma fibrinogen was determined using the method described by Clauss. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| umol/L | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=44, 43) | -3.971 ± 0.246 | -3.839 ± 0.244 |
| Change at Day 14 (n=43, 42) | 0.051 ± 0.521 | -0.148 ± 0.519 |
| Change at Day 28 (n=32, 40) | 0.147 ± 0.599 | -0.091 ± 0.524 |
| Change at Day 56 (n=31, 42) | -2.155 ± 0.533 | -1.162 ± 0.462 |
Blood was collected and analyzed for serum glucose levels. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| mmol/L | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 41) | 1.617 ± 0.426 | 1.027 ± 0.397 |
| Change at Day 14 (n=33, 41) | 1.000 ± 0.300 | 0.432 ± 0.270 |
| Change at Day 28 (n=28, 40) | 0.067 ± 0.156 | -0.020 ± 0.129 |
| Change at Day 56 (n=27, 40) | 0.255 ± 0.272 | 0.226 ± 0.230 |
Blood was collected and analyzed for serum glucose levels. A negative change from Baseline indicated improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, visit, and treatment by visit interaction.
| mmol/L | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=46, 45) | 1.767 ± 0.408 | 0.973 ± 0.408 |
| Change at Day 14 (n=42, 45) | 0.942 ± 0.254 | 0.364 ± 0.246 |
| Change at Day 28 (n=33, 44) | 0.061 ± 0.139 | -0.008 ± 0.119 |
| Change at Day 56 (n=32, 43) | 0.189 ± 0.235 | 0.215 ± 0.210 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
| liters | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 41) | 0.051 ± 0.031 | 0.010 ± 0.029 |
| Change at Day 14 (n=33, 41) | 0.083 ± 0.035 | 0.028 ± 0.031 |
| Change at Day 28 (n=28, 40) | 0.095 ± 0.037 | 0.001 ± 0.031 |
| Change at Day 56 (n=27, 40) | 0.064 ± 0.039 | 0.010 ± 0.033 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
| liters | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=47, 45) | 0.063 ± 0.027 | 0.012 ± 0.028 |
| Change at Day 14 (n= 43, 45) | 0.062 ± 0.029 | 0.018 ± 0.029 |
| Change at Day 28 (n=33, 44) | 0.084 ± 0.031 | -0.003 ± 0.028 |
| Change at Day 56 (n=32, 44) | 0.050 ± 0.034 | 0.005 ± 0.030 |
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
| liters | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 41) | 0.002 ± 0.060 | 0.057 ± 0.056 |
| Change at Day 14 (n=33, 41) | 0.039 ± 0.062 | 0.166 ± 0.056 |
| Change at Day 28 (n=28, 40) | 0.039 ± 0.072 | 0.075 ± 0.062 |
| Change at Day 56 (n=27, 40) | 0.044 ± 0.072 | 0.086 ± 0.062 |
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
| liters | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=47, 45) | 0.048 ± 0.052 | 0.062 ± 0.053 |
| Change at Day 14 (n=43, 45) | 0.046 ± 0.054 | 0.146 ± 0.053 |
| Change at Day 28 (n=33, 44) | 0.053 ± 0.062 | 0.067 ± 0.057 |
| Change at Day 56 (n=32, 44) | 0.034 ± 0.065 | 0.084 ± 0.058 |
FEV1/FVC is the percentage of the vital capacity which is expired in the first second of maximal expiration. In healthy patients the FEV1/FVC is usually around 70%. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
| percent | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=37, 41) | 1.575 ± 0.933 | -1.064 ± 0.870 |
| Change at Day 14 (n=33, 41) | 1.874 ± 1.012 | -1.796 ± 0.914 |
| Change at Day 28 (n=28, 40) | 2.350 ± 1.138 | -1.029 ± 0.982 |
| Change at Day 56 (n=27, 40) | 1.636 ± 0.951 | -1.669 ± 0.828 |
FEV1/FVC is the percentage of the vital capacity which is expired in the first second of maximal expiration. In healthy patients the FEV1/FVC is usually around 70%. A positive change from Baseline indicates an improvement. A Mixed Model Repeated Measurement (MMRM) was used for analysis with Baseline value, treatment, visit, and treatment by visit interaction as covariates.
| percent | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 7 (n=47, 45) | 1.282 ± 0.795 | -1.128 ± 0.799 |
| Change at Day 14 (n=43, 45) | 1.394 ± 0.850 | -1.830 ± 0.834 |
| Change at Day 28 (n=33, 44) | 2.045 ± 0.974 | -1.198 ± 0.888 |
| Change at Day 56 (n=32, 44) | 1.393 ± 0.827 | -1.881 ± 0.765 |
The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst).
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Week 1 (n=27, 34) | 19.4 ± 6.65 | 19.2 ± 7.20 |
| Week 2 (n=28, 36) | 17.1 ± 7.86 | 17.1 ± 7.48 |
| Week 3 (n=24, 37) | 15.9 ± 7.84 | 16.0 ± 7.90 |
| Week 4 (n=23, 38) | 15.1 ± 7.85 | 15.8 ± 8.42 |
| Week 5 (n=21, 37) | 14.2 ± 7.41 | 14.9 ± 8.04 |
| Week 6 (n=19, 37) | 12.9 ± 6.85 | 15.4 ± 8.23 |
| Week 7 (n=20, 33) | 13.9 ± 8.93 | 14.7 ± 8.48 |
| Week 8 (n=18, 30) | 12.8 ± 7.85 | 15.6 ± 8.25 |
The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst).
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Week 1 (n=37, 38) | 20.4 ± 7.26 | 19.3 ± 7.03 |
| Week 2 (n=37, 40) | 18.2 ± 8.54 | 17.2 ± 7.32 |
| Week 3 (n=29, 41) | 16.2 ± 8.08 | 16.1 ± 7.73 |
| Week 4 (n=27, 42) | 16.0 ± 8.21 | 15.9 ± 8.26 |
| Week 5 (n=25, 41) | 14.0 ± 7.28 | 15.1 ± 7.93 |
| Week 6 (n=23, 41) | 12.9 ± 6.58 | 15.4 ± 8.12 |
| Week 7 (n=24, 37) | 13.5 ± 8.38 | 14.8 ± 8.44 |
| Week 8 (n=19, 30) | 13.0 ± 7.68 | 15.6 ± 8.25 |
The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst). A negative change from Baseline indicates improvement. Covariates for MMRM are stable state value, treatment, time point, and treatment by time point interaction.
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=27, 34) | 6.448 ± 1.503 | 2.695 ± 1.096 |
| Change at Week 2 (n=28, 36) | 3.778 ± 1.239 | 0.804 ± 0.911 |
| Change at Week 3 (n=24, 37) | 2.002 ± 0.915 | 0.278 ± 0.669 |
| Change at Week 4 (n=23, 38) | 0.559 ± 0.739 | 0.277 ± 0.536 |
| Change at Week 5 (n=21, 37) | -0.412 ± 0.613 | -0.392 ± 0.448 |
| Change at Week 6 (n=19, 37) | -0.924 ± 0.411 | -0.062 ± 0.297 |
| Change at Week 7 (n=20, 33) | -0.228 ± 0.342 | 0.048 ± 0.253 |
| Change at Week 8 (n=18, 30) | 0.002 ± 0.059 | -0.048 ± 0.044 |
The CAT is a short, validated, patient-completed questionnaire to assess the impact of COPD on health status. It comprises 8 questions that cover a broad range of effects of COPD on patients' health. Each question is scored in a range between 0 and 5, with the higher end indicating a higher impact of COPD on the patient's wellbeing. The CAT Total score ranges from 0 best) to 40 (Worst). A negative change from Baseline indicates improvement. Covariates for MMRM are stable state value, treatment, time point, and treatment by time point interaction.
| scores on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Week 1 (n=37, 38) | 6.232 ± 1.424 | 3.009 ± 1.052 |
| Week 2 (n=37, 40) | 3.558 ± 1.178 | 1.074 ± 0.876 |
| Week 3 (n=29, 41) | 2.044 ± 0.847 | 0.458 ± 0.627 |
| Week 4 (n=27, 42) | 0.545 ± 0.732 | 0.429 ± 0.534 |
| Week 5 (n=25, 41) | -0.347 ± 0.621 | -0.170 ± 0.459 |
| Week 6 (n=23, 41) | -0.668 ± 0.402 | -0.043 ± 0.295 |
| Week 7 (n=24, 37) | -0.121 ± 0.310 | 0.014 ± 0.232 |
| Week 8 (n=19, 30) | -0.010 ± 0.061 | -0.031 ± 0.045 |
The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status.
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Week 1 (n=25, 35) | 45.2 ± 8.54 | 45.1 ± 8.50 |
| Week 2 (n=28, 36) | 41.2 ± 11.39 | 42.4 ± 9.07 |
| Week 3 (n=24, 38) | 38.8 ± 11.22 | 40.0 ± 10.22 |
| Week 4 (n=23, 38) | 38.3 ± 11.00 | 40.2 ± 11.26 |
| Week 5 (n=21, 37) | 35.9 ± 11.11 | 39.1 ± 10.55 |
| Week 6 (n=19, 37) | 35.1 ± 9.75 | 39.4 ± 11.05 |
| Week 7 (n=20, 34) | 35.6 ± 13.69 | 38.7 ± 12.05 |
| Week 8 (n=18, 32) | 34.4 ± 11.50 | 39.4 ± 11.34 |
The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status.
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Week 1 (n=35, 39) | 45.6 ± 9.19 | 45.0 ± 8.39 |
| Week 2 (n=37, 40) | 42.0 ± 11.07 | 42.3 ± 8.81 |
| Week 3 (n=29, 42) | 39.0 ± 11.27 | 39.9 ± 9.82 |
| Week 4 (n=27, 42) | 38.8 ± 11.37 | 40.3 ± 10.90 |
| Week 5 (n=25, 41) | 35.3 ± 11.03 | 39.1 ± 10.13 |
| Week 6 (n=23, 41) | 33.9 ± 10.45 | 39.4 ± 10.62 |
| Week 7 (n=24, 38) | 34.3 ± 13.09 | 38.7 ± 11.52 |
| Week 8 (n=19, 33) | 34.0 ± 11.30 | 39.6 ± 11.25 |
The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, time point, treatment by time point and baseline by time point interaction.
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=25, 35) | 6.182 ± 3.271 | 4.753 ± 2.385 |
| Change at Week 2 (n=28, 36) | 4.423 ± 2.538 | 1.558 ± 1.864 |
| Change at Week 3 (n=24, 38) | 2.080 ± 2.041 | 0.317 ± 1.494 |
| Change at Week 4 (n=23, 38) | 0.002 ± 2.003 | 0.657 ± 1.459 |
| Change at Week 5 (n=21, 37) | -1.058 ± 1.748 | -0.307 ± 1.276 |
| Change at Week 6 (n=19, 37) | -1.688 ± 1.015 | -0.002 ± 0.738 |
| Change at Week 7 (n=20, 34) | -0.773 ± 0.698 | 0.002 ± 0.514 |
| Change at Week 8 (n=18, 32) | -0.190 ± 0.259 | -0.154 ± 0.191 |
The EXACT-PRO questionnaire is a new, validated, and standardized measure to evaluate the frequency, severity, and duration of COPD exacerbations. It is a 14-item daily diary, and scores range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are baseline value, treatment, time point, treatment by time point and baseline by time point interaction.
| scores on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Week 1 (n=35, 39) | 7.163 ± 2.859 | 4.697 ± 2.077 |
| Week 2 (n=37, 40) | 4.839 ± 2.259 | 1.433 ± 1.652 |
| Week 3 (n=29, 42) | 2.988 ± 1.870 | 0.179 ± 1.363 |
| Week 4 (n=27, 42) | 0.909 ± 1.861 | 0.743 ± 1.344 |
| Week 5 (n=25, 41) | -0.657 ± 1.554 | -0.318 ± 1.129 |
| Week 6 (n=23, 41) | -0.889 ± 0.976 | -0.140 ± 0.706 |
| Week 7 (n=24, 38) | -0.311 ± 0.654 | -0.075 ± 0.479 |
| Week 8 9n=19, 33) | -0.240 ± 0.244 | -0.115 ± 0.178 |
Morning post-medication PEF (the best of 3 attempts measured with a mini-Wright peak-flow meter) was recorded in a daily diary. A positive change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
| liters/minute | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=37, 38) | -16.551 ± 5.144 | -9.915 ± 4.442 |
| Change at Week 2 (n=35, 40) | -6.067 ± 4.564 | -0.304 ± 3.899 |
| Change at Week 3 (n=35, 40) | -4.996 ± 3.914 | 0.687 ± 3.360 |
| Change at Week 4 (n=29, 39) | -4.595 ± 3.421 | -0.420 ± 2.737 |
| Change at Week 5 (n=28, 38) | -3.557 ± 4.061 | -1.224 ± 3.287 |
| Change at Week 6 (n=27, 37) | -3.795 ± 4.546 | -5.559 ± 3.680 |
| Change at Week 7 (n=27, 36) | -7.178 ± 5.212 | -4.186 ± 4.264 |
| Change at Week 8 (n=27, 35) | -2.877 ± 5.388 | -0.956 ± 4.418 |
Morning post-medication PEF (the best of 3 attempts measured with a mini-Wright peak-flow meter) was recorded in a daily diary. A positive change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
| liters/minute | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=46, 42) | -13.958 ± 4.147 | -8.447 ± 3.865 |
| Change at Week 2 (n=44, 44) | -5.776 ± 3.772 | 1.029 ± 3.488 |
| Change at Week 3 (n=44, 44) | -5.360 ± 3.676 | 2.038 ± 3.421 |
| Change at Week 4 (n=37, 43) | -6.660 ± 3.546 | 1.133 ± 3.126 |
| Change at Week 5 (n=33, 42) | -5.568 ± 3.847 | 0.269 ± 3.396 |
| Change at Week 6 (n=32, 41) | -2.186 ± 3.515 | -4.596 ± 3.076 |
| Change at Week 7 (n=31, 40) | -8.513 ± 4.544 | -1.974 ± 3.952 |
| Change at Week 8 (n=31, 39) | -4.563 ± 4.741 | 0.950 ± 4.091 |
Any increase in the following respiratory symptoms: dyspnea, sputum purulence, sputum amount, wheeze, sore throat, cough, fever, symptoms of a common cold, ie, nasal congestion and discharge over the previous 24 hours were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=38, 42) | 2.930 ± 0.286 | 2.587 ± 0.254 |
| Change at Week 2 (n=37, 42) | 1.130 ± 0.314 | 1.331 ± 0.272 |
| Change at Week 3 (n=35, 42) | 0.906 ± 0.299 | 0.790 ± 0.258 |
| Change at Week 4 (n=30, 40) | 0.552 ± 0.298 | 0.922 ± 0.248 |
| Change at Week 5 (n=29, 39) | 0.413 ± 0.305 | 0.882 ± 0.254 |
| Change at Week 6 (n=28, 39) | 0.141 ± 0.310 | 0.681 ± 0.258 |
| Change at Week 7 (n=27, 37) | 0.442 ± 0.294 | 0.673 ± 0.243 |
| Change at Week 8 (n=27, 36) | 0.626 ± 0.361 | 0.612 ± 0.297 |
Any increase in the following respiratory symptoms: dyspnea, sputum purulence, sputum amount, wheeze, sore throat, cough, fever, symptoms of a common cold, ie, nasal congestion and discharge over the previous 24 hours were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=48, 46) | 3.110 ± 0.257 | 2.593 ± 0.246 |
| Change at Week 2 (n=47, 46) | 1.171 ± 0.285 | 1.402 ± 0.267 |
| Change at Week 3 (n=44, 46) | 0.850 ± 0.267 | 0.802 ± 0.250 |
| Change at Week 4 (n=38, 44) | 0.751 ± 0.312 | 0.924 ± 0.282 |
| Change at Week 5 (n=34, 43) | 0.437 ± 0.287 | 0.907 ± 0.259 |
| Change at Week 6 (n=33, 43) | 0.041 ± 0.257 | 0.661 ± 0.231 |
| Change at Week 7 (n=31, 41) | 0.503 ± 0.247 | 0.533 ± 0.216 |
| Change at Week 8 (n=31, 40) | 0.451 ± 0.274 | 0.530 ± 0.237 |
Any changes in the participant's usual treatment were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=38, 42) | 0.849 ± 0.194 | 0.769 ± 0.174 |
| Change at Week 2 (n=37, 42) | 0.682 ± 0.190 | 0.804 ± 0.167 |
| Change at Week 3 (n=35, 42) | 0.281 ± 0.115 | 0.188 ± 0.099 |
| Change at Week 4 (n=30, 40) | 0.185 ± 0.118 | 0.217 ± 0.099 |
| Change at Week 5 (n=29, 39) | 0.130 ± 0.123 | 0.263 ± 0.103 |
| Change at Week 6 (n=28, 39) | 0.128 ± 0.130 | 0.204 ± 0.108 |
| Change at Week 7 (n=27, 37) | 0.112 ± 0.117 | 0.135 ± 0.097 |
| Change at Week 8 (n=27, 36) | 0.122 ± 0.101 | 0.127 ± 0.084 |
Any changes in the participant's usual treatment were recorded in a daily diary. Diaries Symptom Score range from 0 to 100, with higher scores indicating worse health status. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
| score on a scale | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=48, 46) | 0.787 ± 0.170 | 0.730 ± 0.162 |
| Change at Week 2 (n=47, 46) | 0.767 ± 0.172 | 0.780 ± 0.161 |
| Change at Week 3 (n=44, 46) | 0.338 ± 0.103 | 0.177 ± 0.095 |
| Change at Week 4 (n=38, 44) | 0.379 ± 0.144 | 0.206 ± 0.129 |
| Change at Week 5 (n=34, 43) | 0.191 ± 0.107 | 0.244 ± 0.096 |
| Change at Week 6 (n=33, 43) | 0.127 ± 0.107 | 0.196 ± 0.096 |
| Change at Week 7 (n=31, 41) | 0.179 ± 0.116 | 0.156 ± 0.103 |
| Change at Week 8 (n=31, 40) | 0.084 ± 0.086 | 0.171 ± 0.075 |
Estimates of the length of time the participants were out of their own home on the previous day were recorded in a daily diary. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
| hours | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=34, 34) | -1.313 ± 0.416 | -0.105 ± 0.391 |
| Change at Week 2 (n=34, 38) | -0.974 ± 0.359 | -0.328 ± 0.333 |
| Change at Week 3 (n=34, 40) | -1.077 ± 0.374 | 0.226 ± 0.335 |
| Change at Week 4 (n=28, 39) | -1.131 ± 0.414 | -0.306 ± 0.354 |
| Change at Week 5 (n=26, 38) | -0.826 ± 0.465 | 0.280 ± 0.407 |
| Change at Week 6 (n=25, 35) | -1.154 ± 0.448 | -0.062 ± 0.386 |
| Change at Week 7 (n=26, 35) | -1.194 ± 0.449 | -0.340 ± 0.394 |
| Change at Week 8 (n=26, 34) | -0.812 ± 0.532 | 0.037 ± 0.458 |
Estimates of the length of time the participants were out of their own home on the previous day were recorded in a daily diary. A negative change from Baseline indicates improvement. Covariates for Mixed Model Repeated Measurement (MMRM) are stable state value, treatment, time point, and treatment by time point interaction.
| hours | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Week 1 (n=42, 38) | -1.472 ± 0.353 | -0.276 ± 0.344 |
| Change at Week 2 (n=43, 42) | -1.305 ± 0.319 | -0.472 ± 0.307 |
| Change at Week 3 (n=42, 44) | -1.314 ± 0.343 | 0.099 ± 0.324 |
| Change at Week 4 (n=35, 43) | -1.328 ± 0.357 | -0.266 ± 0.325 |
| Change at Week 5 (n=31, 42) | -0.833 ± 0.402 | 0.158 ± 0.369 |
| Change at Week 6 (n=30, 39) | -1.271 ± 0.372 | -0.247 ± 0.344 |
| Change at Week 7 (n=30, 39) | -1.144 ± 0.363 | -0.478 ± 0.333 |
| Change at Week 8 (n=30, 38) | -0.714 ± 0.443 | -0.068 ± 0.401 |
Exacerbation length is the period from start of increased symptoms to end of increased symptoms; the last day of an exacerbation was to be followed by 2 days without symptom entries in the diary.
| days | Roflumilast 500 μg | Placebo |
|---|---|---|
| Exacerbation Length (Initial Approach) | 12.0 (8.0 to 18.0) | 14.0 (10.0 to 17.0) |
Exacerbation length is the period from start of increased symptoms to end of increased symptoms; the last day of an exacerbation was to be followed by 2 days without symptom entries in the diary.
| days | Roflumilast 500 μg | Placebo |
|---|---|---|
| Exacerbation Length (Extended Approach) | 13.0 (9.0 to 19.0) | 14.0 (11.0 to 17.0) |
Carotid-femoral aortic pulse wave velocity (aPWV) will be measured in a subset of participants to determine changes in arterial stiffness. A negative change from Baseline indicates improvement. Covariates for MMRM are baseline value, treatment, visit, and treatment by visit interaction.
| meters/second | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 14 (n=18, 24) | -0.047 ± 0.337 | -0.343 ± 0.290 |
| Change at Day 28 (n=14, 24) | -0.380 ± 0.413 | -0.474 ± 0.321 |
Carotid-femoral aortic pulse wave velocity (aPWV) will be measured in a subset of participants to determine changes in arterial stiffness. A negative change from Baseline indicates improvement. Covariates for MMRM are baseline value, treatment, visit, and treatment by visit interaction.
| meters/second | Roflumilast 500 μg | Placebo |
|---|---|---|
| Change at Day 14 (n=28, 28) | -0.128 ± 0.247 | -0.326 ± 0.245 |
| Change at Day 28 (n=19, 28) | -0.316 ± 0.323 | -0.511 ± 0.273 |
Collected over Signing of informed consent until Follow-up Visit (Up to 56 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast 500 μg (Initial Approach) | — | 4/38 (10.5%) | 35/38 (92.1%) |
| Placebo (Initial Approach) | — | 1/43 (2.3%) | 25/43 (58.1%) |
| Roflumilast 500 µg (Extended Approach) | — | 4/48 (8.3%) | 44/48 (91.7%) |
| Placebo (Extended Approach) | — | 1/47 (2.1%) | 28/47 (59.6%) |
| Event | Roflumilast 500 μg (Initial Approach) | Placebo (Initial Approach) | Roflumilast 500 µg (Extended Approach) | Placebo (Extended Approach) |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/38 | 0/43 | 1/48 | 0/47 |
| PneumoniaInfections and infestations | 1/38 | 0/43 | 1/48 | 0/47 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/38 | 0/43 | 1/48 | 0/47 |
| Supraventricular tachycardiaCardiac disorders | 1/38 | 0/43 | 1/48 | 0/47 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/38 | 1/43 | 0/48 | 1/47 |
| Event | Roflumilast 500 μg (Initial Approach) | Placebo (Initial Approach) | Roflumilast 500 µg (Extended Approach) | Placebo (Extended Approach) |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 25/38 | 10/43 | 32/48 | 11/47 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 17/38 | 13/43 | 19/48 | 15/47 |
| InsomniaPsychiatric disorders | 12/38 | 2/43 | 14/48 | 2/47 |
| NauseaGastrointestinal disorders | 6/38 | 3/43 | 9/48 | 3/47 |
| DizzinessNervous system disorders | 6/38 | 1/43 | 6/48 | 1/47 |
| Decreased appetiteMetabolism and nutrition disorders | 4/38 | 2/43 | 6/48 | 2/47 |
| HeadacheNervous system disorders | 3/38 | 2/43 | 4/48 | 2/47 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/38 | 1/43 | 3/48 | 1/47 |
| VomitingGastrointestinal disorders | 0/38 | 0/43 | 3/48 | 1/47 |
| Abdominal painGastrointestinal disorders | 2/38 | 1/43 | 0/48 | 0/47 |
Full Analysis set consisted of all randomized patients who received at least 1 dose of investigational medicinal product (IMP)
| Age, Customized(participants) | Roflumilast 500 μg | Placebo | Total |
|---|---|---|---|
| ≤ 65 years | 7 | 11 | 18 |
| > 65 years | 31 | 32 | 63 |
| Gender(Participants) | Roflumilast 500 μg | Placebo | Total |
|---|---|---|---|
| Female | 16 | 15 | 31 |
| Male | 22 | 28 | 50 |
| Race/Ethnicity, Customized(participants) | Roflumilast 500 μg | Placebo | Total |
|---|---|---|---|
| Asian | 2 | 1 | 3 |
| White | 36 | 42 | 78 |
| Smoking status(participants) | Roflumilast 500 μg | Placebo | Total |
|---|---|---|---|
| Non-smoker | 0 | 0 | 0 |
| Current smoker | 8 | 11 | 19 |
| Former smoker | 30 | 32 | 62 |
| Baseline COPD Assessment Test (CAT) Total Score(participants) | Roflumilast 500 μg | Placebo | Total |
|---|---|---|---|
| < 10 | 2 | 3 | 5 |
| ≥ 10 | 16 | 25 | 41 |
| Missing | 20 | 15 | 35 |
| Weight Category by Body Mass Index (BMI)(participants) | Roflumilast 500 μg | Placebo | Total |
|---|---|---|---|
| Underweight | 3 | 0 | 3 |
| Normal Weight | 15 | 18 | 33 |
| Overweight | 11 | 15 | 26 |
| Obese | 9 | 9 | 18 |
| Missing | 0 | 1 | 1 |
| Chronic Bronchitis(participants) | Roflumilast 500 μg | Placebo | Total |
|---|---|---|---|
| No | 14 | 17 | 31 |
| Yes | 24 | 26 | 50 |
| Historical Chronic Obstructive Pulmonary Disease (COPD) Exacerbations(participants) | Roflumilast 500 μg | Placebo | Total |
|---|---|---|---|
| < 2 | 28 | 28 | 56 |
| ≥ 2 | 10 | 15 | 25 |
The record gives a start of Feb 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 2 years 7 months after primary completion. A results delay was requested in Feb 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Pulmonary Disease, Chronic Obstructive →